CTCs in metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-642-28160-0_18PMID 22527507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

  2012cited by this paper
• Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

  2012cited by this paper
• Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

  2011cited by this paper
• Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

  2011cited by this paper
• Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

  2011cited by this paper
• Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression

  2011cited by this paper
• Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.

  2011cited by this paper
• Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients

  2011cited by this paper
• Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal

  2011cited by this paper
• Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy

  2011cited by this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

  2011cited by this paper
• Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

  2011cited by this paper
• Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer.

  2011cited by this paper
• Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

  2011cited by this paper
• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

  2011cited by this paper
• mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients

  2011cited by this paper
• Circulating tumor cells: approaches to isolation and characterization

  2011cited by this paper
• Molecular Biomarker Analyses Using Circulating Tumor Cells

  2010cited by this paper
• Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.

  2010cited by this paper
• Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.

  2010cited by this paper
• Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

  2010cited by this paper
• Circulating tumour cells in cancer patients: challenges and perspectives.

  2010cited by this paper
• Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

  2010cited by this paper
• Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

  2010cited by this paper
• Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

  2010cited by this paper
• Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

  2009cited by this paper
• Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

  2009cited by this paper
• Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

  2009cited by this paper
• Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

  2009cited by this paper
• Circulating tumor cells in solid tumor in metastatic and localized stages.

  2009cited by this paper
• Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications.

  2008cited by this paper
• Circulating tumor cells in metastatic breast cancer

  2008cited by this paper
• Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

  2006cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction.

  2000cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• Role of organ selectivity in the determination of metastatic patterns of B16 melanoma.

  1980cited by this paper

• Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer

  2026cites this paper
• Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies

  2025cites this paper
• Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

  2025cites this paper
• Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy

  2023cites this paper
• Phenotyping of rare circulating cells in the blood of non-metastatic breast cancer patients using microfluidic Labyrinth technology.

  2022cites this paper
• Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis

  2022cites this paper
• Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients

  2021cites this paper
• Relationship between Stemness, Reactive Oxygen Species, and Epithelial-to-Mesenchymal Transition in Model Circulating Tumor Cells

  2021cites this paper
• Summer School in Flow Cytometry for Immunology: Report From a Successful ESCCA Experience

  2019cites this paper
• CTCs‐derived xenograft development in a triple negative breast cancer case

  2018cites this paper
• Clinical Utility of Circulating Tumor Cells – A Clinician’s Current View

  2017cites this paper
• Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells

  2017cites this paper
• Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures.

  2017cites this paper
• Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer

  2016cites this paper
• Bone Marrow Micrometastases and Circulating Tumor Cells

  2016cites this paper
• Plasma S100P level as a novel prognostic marker of metastatic breast cancer

  2016cites this paper
• Detecting Tumor Metastases: The Road to Therapy Starts Here.

  2016cites this paper
• A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells

  2015cites this paper
• The Role of CTCs as Tumor Biomarkers.

  2015cites this paper
• AWARD NUMBER: W81XWH-12-1-0076 TITLE: Development of Laser-Mediated Nanodroplet Real-Time PCR on Circulating Tumor Cells (CTC) by Microfilter Platform PRINCIPAL INVESTIGATOR:

  2015cites this paper
• Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program

  2015cites this paper
• Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.

  2014cites this paper
• Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer

  2014cites this paper
• Circulating tumor cells as promising novel biomarkers in solid cancers

  2014cites this paper
• Real‐time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry

  2014cites this paper
• Biopsies: next-generation biospecimens for tailoring therapy

  2013cites this paper
• Advanced technologies for studying circulating tumor cells at the protein level

  2013cites this paper
• Detection of circulating tumor cells in breast cancer with a refined immunomagnetic nanoparticle enriched assay and nested-RT-PCR.

  2013cites this paper
• Essentials of circulating tumor cells for clinical research and practice.

  2013cites this paper
• Metastatic Determinants: Breast Tumour Cells in Circulation

  2013cites this paper
• Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

  2012cites this paper
• Molecular Medicine in Practice Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer

  2012cites this paper
• Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

  2012cites this paper